Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBudesonide is a synthetic anti-inflammatory glucocorticoid that displays chemopreventive activity. Prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. Reverses DNA hypomethylation and modulates expression of cancer related genes.
Budesonide is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
M. Wt | 430.53 |
Formula | C25H34O6 |
Storage | Store at RT |
Purity | ≥98% (HPLC) |
CAS Number | 51333-22-3 |
PubChem ID | 5281004 |
InChI Key | VOVIALXJUBGFJZ-KWVAZRHASA-N |
Smiles | O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H]5[C@](C(CO)=O)4OC(CCC)O5)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 43.05 | 100 | |
ethanol | 21.52 | 50 |
The following data is based on the product molecular weight 430.53. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.32 mL | 11.61 mL | 23.23 mL |
5 mM | 0.46 mL | 2.32 mL | 4.65 mL |
10 mM | 0.23 mL | 1.16 mL | 2.32 mL |
50 mM | 0.05 mL | 0.23 mL | 0.46 mL |
References are publications that support the biological activity of the product.
Spencer et al (1995) Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50 854 PMID: 8586030
Pereira et al (2006) Modulation by budes. of DNA methylation and mRNA expression in mouse lung tumors. Int.J.Cancer 120 1150 PMID: 17163412
Wattenberg et al (2007) Chemoprevention of pulmonary carcinogenesis by aerosolized budes. in female A/J mice. Cancer Res. 57 5489 PMID: 9407956
If you know of a relevant reference for Budesonide, please let us know.
Keywords: Budesonide, Budesonide supplier, Synthetic, glucocorticoid, anti-inflammatory, chemopreventive, Receptors, Glucocorticoid, Receptor, 2671, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Budesonide include:
Kim et al (2016) Glucocorticoids Have Opposing Effects on Liver Fibrosis in Hepatic Stellate and Immune Cells. Front Endocrinol (Lausanne) NULL me20161029 PMID: 27355192
Luo (2017) β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro. Scientific Reports 7 39905 PMID: 28051147
Liu et al (2015) A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype-3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells. Mol Endocrinol 11 4121 PMID: 25672589
Do you know of a great paper that uses Budesonide from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Budesonide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.